Drug Profile
BBT 015
Alternative Names: BBT-015Latest Information Update: 19 Jun 2023
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives
- Mechanism of Action Immunostimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute radiation syndrome; Neutropenia
Most Recent Events
- 19 Jun 2023 BBT 015 is still in phase I trials for Acute radiation syndrome in USA (SC) (Bolder Biotechnology pipeline, June 2023)
- 19 Jun 2023 BBT 015 is still in phase I trials for Neutropenia in USA (SC) (Bolder Biotechnology pipeline, June 2023)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Acute-radiation-syndrome(In volunteers) in USA (SC, Injection)